Drugs / pUMVC3-IGFBP2-HER2-IGF1R
pUMVC3-IGFBP2-HER2-IGF1R
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02780401 | Sep 2016 → Oct 2020 | Her2-receptor negative breast cancer, axillary neoplasm, female breast carcinoma | University of Washington | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04329065 | Apr 2022 → Dec 2026 expected | female breast carcinoma | University of Washington | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03384914 Comparator | Feb 2018 → Dec 2025 overdue | HER2 positive breast carcinoma, female breast carcinoma, male breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pUMVC3-IGFBP2-HER2-IGF1R | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04329065 ↗ |
| Known as | pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02780401 ↗ |
| Known as | WOKVAC Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03384914 ↗ |
| Modality | Vaccine | “Th1 selective multiantigen, polyepitope plasmid-DNA vaccine encoding segments of IGFBP-2, HER2, and IGF-IR” PMID 42082270 ↗ May 2026 |
| Route | Other | “via intradermal injection” NCT03384914 ↗ |